ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
Most recently, Gilson served as a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, covering biotechnology companies. Prior to joining Canaccord, she held biotechnology equity research roles at Jefferies, LLC; Instinet, LLC (Nomura Securities); Oppenheimer & Co. Inc.; and Goldman Sachs. Ms. Gilson earned her B.S. in Business Administration from the University of Southern California.
Kite And Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
A Gilead Sciences company, Kite announced Tmunity’s next-generation CAR-T therapies and technology will complement its own cell therapy research capabilities. Kite’s acquisition of Tmunity, founded by Carl June, creates a strong bridge between the BioHealth Capital Region, where Kite maintains its manufacturing capabilities in Frederick, and the Greater Philadelphia biohub.
Arcellx And Kite Announce Strategic Collaboration To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.
Jeff Galvin, the CEO of American Gene TechnologiesⓇ, one of the leading biotech companies in Maryland, has championed the state as “DNA Valley.” And Galvin should know: he came to Maryland after a successful career in Silicon Valley and sees parallels between the early days of an emerging Silicon Valley and what’s going on today in DNA Valley, which currently stretches from Montgomery County and Frederick, Maryland all the way up to Baltimore.
We’re excited to announce this year’s finalists for the third annual 2022 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
The newly minted public company, a clinical-stage provider of cell therapies for cancer and autoimmune diseases, has signed a lease for 60,000 square feet at 800 King Farm Blvd., a roughly 215,000-square-foot office building that Miami-based Banyan Street Capital will convert into office and lab space for life sciences companies. Banyan Street had acquired an ownership stake in 800 King Farm, as well as 700 and 702 King Farm Blvd., in 2020, according to JLL.
Arcellx Announces Closing Of Upsized Public Offering Of Common Stock And Underwriters’ Full Exercise Of Option To Purchase Additional Shares
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its upsized public offering of 8,050,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares of common stock, at a price to the public of $16.00 per share. The aggregate gross proceeds raised in the offering were $128.8 million, before deducting underwriting discounts and commissions and offering expenses, payable by Arcellx. All shares in the offering were offered by Arcellx.
Arcellx took a risk by including more patients with a tougher, more aggressive form of multiple myeloma in an early-stage trial for its CAR-T med. But it doesn’t matter, because “any way you slice” it, the small biotech seems to have put up strong enough data to rival the market-leading therapy by Johnson & Johnson and Legend Biotech.
Maryland-based Arcellx presented the latest on CART-ddBCMA, its BCMA-specific CAR-modified T-cell therapy for multiple myeloma, at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Friday.
The data comes from a phase 1 study of patients with relapsed or refractory multiple myeloma, including 31 eligible for an efficacy and safety analysis who had at least three prior lines of treatment. Out of these patients, 21 had “poor prognostic factors,” including extramedullary disease, which means cancer that has spread to form tumors outside the bone marrow in the soft tissues of the body.